H. Benjamín García-González

Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

D. Manzur-Sandoval, J. C. Crispín, S. Valdés-Ferrer, 2022, Molecular Medicine.

Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a randomised, double-blinded, phase 2/3, placebo-controlled trial

D. Manzur-Sandoval, S. Valdés-Ferrer, J. Calva, 2021 .